Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.
The best way to improve cancer treatment is early diagnosis. And this small-cap biotech company may have the key to doing just that, says Matthew Partridge.
A new kind of cancer therapy could make a big difference to survival rates – and transform the fortunes of one big UK drugs company. Matthew Partridge explains.
As life expectancy increases, pharmas and biotechs pioneering treatments for the diseases of old age will profit handsomely, says Matthew Partridge.
The list of holdings in Neil Woodford’s new fund can teach investors a lot about how to construct a portfolio, says David Thornton.
The number of antibiotic-resistant bacteria is rising fast. But the search is on to find new drugs to combat them. Matthew Partridge explains how you could profit.
A spate of merger deals between Big Pharma stocks has given the flagging sector a much-needed boost.
Biotechnology stocks have fallen into a bear market, leaving plenty of bargain buys on the table.
Investors can find a wide range of profitable stocks in the biotech sector. Professional investor Dr Daniel Koller tips three to buy now.
Expanding waistlines are a global health epidemic. Smart investors should fill their boots with the firms that will profit, says Matthew Partridge.
From better drug testing to growing whole new organs – stem cell research is leading to some big investment opportunities. Matthew Partridge tips the best stocks to profit.